Lucid Diagnostics Q1 revenue $1.0M; net loss $18.1M; EsoGuard volume up 10% sequentially

Lucid Diagnostics Inc.

2024-Q1 EPS reported -$0.40 revenue$1,001,000

EsoGuard revenue $1.0M, flat vs Q4'23 but up 124% YoY.
GAAP net loss $18.1M ($0.40/share); non-GAAP adjusted loss $9.4M ($0.21/share).
Cash $24.8M at quarter end; subsequent $11.6M from Series B-1 offering.
MolDX pre-submission meeting scheduled July 17, 2024 for EsoGuard coverage.
EsoGuard test volume 2,420, +10% sequentially and +31% YoY.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Lucid Diagnostics Inc. reported the three months ended March 31, 2024 results: revenue $1.0 million, net income $18.1 million or $(0.40) per common share, EPS $(0.40) per common share.

Period: the three months ended March 31, 2024
Revenue: $1.0 million
Net income: $18.1 million or $(0.40) per common share
EPS: $(0.40) per common share
Result: reported results

Exact text from the filing

regional plans in biomarker legislation states and pilots with national plans. Financial Results ● For the three months ended March 31, 2024, EsoGuard related revenues were $1.0 million. Operating expenses were approximately $11.8 million, which included stock-based compensation expenses of $0.9 million. GAAP net loss attributable to common stockholders was

View on SEC.gov

1047 earnings releases filed in the last 30 days. Browse all earnings releases →

Lucid Diagnostics Inc. filing history →

Source: SEC EDGAR

accession 0001493152-24-019020

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.